In this section
Some antiviral therapies require ID approval. If you have a high-risk outpatient you believe meets the criteria for Covid-19 therapy, please call the Division of Pediatric Infectious Diseases at (414) 337-7070 from 7 a.m. – 3 p.m. or page infectious disease on-call at (414) 266-2460 for urgent or after hours requests. Note- the Covid-19 outpatient treatment and prophylaxis screening form and the Covid-19 treatment review team were retired on 6/14/2023.
Remdesivir for inpatient use and Paxlovid prescriptions dispensed by a community pharmacy do not require ID approval. Advice about the potential benefits of antiviral treatment can be solicited by paging infectious disease on-call.
Covid-19 treatment guidelines
- Children’s Wisconsin’s guidelines for outpatient Covid-19 treatment and prevention (PDF) updated 06/14/23
- SARS-CoV-2 anti-viral education (PDF) Last updated 06/14/23
- MIS-C primary care guidelines (PDF)
- MIS-C flowchart (PDF)
- MIS-C recorded webinar
- Care after COVID-19
FDA fact sheets for health care providers
For the treatment of mild-to-moderate Covid-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe Covid-19, including hospitalization or death. See Children's Wisconsin guidelines for community Paxlovid use.
Information for families
Use Chrome browser for best results.
- Health care providers who prescribe Paxlovid under the emergency use authorization (EUA) are required to provide patients and/or their caregivers with information consistent with the conditions of authorization listed in the EUA, and provide a copy of the fact sheet for patients, parents and caregivers.